Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zinc picolinate is a chelated form of the essential mineral zinc, where elemental zinc is bound to picolinic acid to enhance its absorption and bioavailability compared to inorganic salts like zinc oxide or zinc gluconate. It is primarily utilized as a dietary supplement to support immune function, DNA repair, and cellular metabolism. In a clinical context, it is being evaluated in the Phase 2 'Thinking Zinc' study by the University of New Mexico to mitigate the adverse effects of environmental metal toxicity (such as from mine waste) in tribal populations. The rationale for its use is that restoring zinc sufficiency can counteract mechanisms of metal toxicity by inducing the expression of metallothioneins — intracellular proteins that sequester toxic heavy metals — and by supporting the function of zinc-dependent enzymes involved in DNA repair and immune response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zinc picolinate.